Federal grants to Vivreon Biosciences LLC
Vivreon Biosciences LLC in San Diego, California received $12.9 million in federal grants from fiscal 2021 to 2025, across 12 awards. Its largest program was Aging Research, with $4.7 million. In fiscal 2025 it was awarded $4.1 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$12.9 million
- Awards12
- Awarded in FY 2025$4.1 million
- Largest award$2.8 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $500,431 |
| FY 2022 | 4 | $3.2 million |
| FY 2023 | 3 | $1.9 million |
| FY 2024 | 4 | $3.2 million |
| FY 2025 | 3 | $4.1 million |
Programs that fund Vivreon Biosciences LLC
| Program | Awards | Amount |
|---|---|---|
| Aging Research | 3 | $4.7 million |
| Drug Use and Addiction Research Programs | 2 | $2.9 million |
| Allergy and Infectious Diseases Research | 2 | $2.3 million |
| Cancer Treatment Research | 1 | $1.9 million |
| Arthritis, Musculoskeletal and Skin Diseases Research | 3 | $804,167 |
| Cardiovascular Diseases Research | 1 | $352,030 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 12 | $12.9 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Development of a novel calcium channel therapeutic for opioid use disorder - vivreon biosciences, LLC 4940 carroll canyon rd., ste. 110 san diego, ca 92121 milton@vivreonbiosciences.com nida RFA-DA-23-021 project summary opioid use disorder (OUD) is the chronic use of opioids that causes clinically | Drug Use and Addiction Research Programs | July 6, 2023 | $2.8 million |
| Preclinical characterization of crac channel inhibitors for the treatment of alzheimer's disease - vivreon biosciences, LLC 4940 carroll canyon rd., ste. 110 san diego, ca 92121 milton@vivreonbiosciences.com nia PAS-19-316 project summary delaying onset of alzheimer’s disease (AD) by 5 years would r | Aging Research | September 14, 2022 | $2.5 million |
| Predevelopment of VV8220, a gut-selective crac channel therapeutic for ulcerative colitis - vivreon biosciences, LLC 4940 carroll canyon rd., ste. 110 san diego, ca 92121 milton@vivreonbiosciences.com niaid PA-23-230 project summary ulcerative colitis (UC) is the most common form of inflammatory bow | Allergy and Infectious Diseases Research | August 1, 2024 | $2.0 million |
| Preclinical characterization of crac channel inhibitors for the treatment of alzheimer's disease - vivreon biosciences, LLC 4940 carroll canyon rd., ste. 110 san diego, ca 92121 milton@vivreonbiosciences.com vivreon biosciences technical assistance and late-stage development, PAR-23-219, NOT-AG-23-0 | Aging Research | June 20, 2025 | $2.0 million |
| Ind-enabling toxicology for a novel CA2+ channel therapeutic to improve outcomes associated with checkpoint inhibitor immunotherapy - vivreon biosciences, LLC 4940 carroll canyon rd. Suite 110 san diego, ca 92121 milton@vivreonbiosciences.com vivreon biosciences, LLC, nci sbir direct to phase II, om | Cancer Treatment Research | May 31, 2022 | $1.9 million |
| Development of a novel calcium channel therapeutic for the treatment of asthma - vivreon biosciences, LLC 4940 carroll canyon rd., ste. 110 san diego, ca 92121 milton@vivreonbiosciences.com nhlbi PA-21-259 project summary severe asthma is a potentially lethal disease that is not fully controlled by | Cardiovascular Diseases Research | April 10, 2023 | $352,030 |
| Development of a novel calcium channel therapeutic for dystrophinopathies - vivreon biosciences, LLC 4940 carroll canyon rd. Suite 110 san diego, ca 92121 milton@vivreonbiosciences.com vivreon biosciences – niams PA-23-230 project summary vivreon is an innovative life sciences company that is develo | Arthritis, Musculoskeletal and Skin Diseases Research | August 28, 2024 | $306,872 |
| Predevelopment of VV8220, a gut-selective crac channel therapeutic for ulcerative colitis - vivreon biosciences, LLC 4940 carroll canyon rd., ste. 110 san diego, ca 92121 milton@vivreonbiosciences.com niaid PA-21-259 project summary ulcerative colitis (UC) is the most common form of inflammatory bow | Allergy and Infectious Diseases Research | April 21, 2022 | $299,989 |
| Predevelopment of VV8321, a novel crac channel therapeutic for the treatment of osteoarthritis - vivreon biosciences, LLC 4940 carroll canyon rd., ste. 110 san diego, ca 92121 milton@vivreonbiosciences.com niams PA-20-260 project summary osteoarthritis (OA) is a progressive arthritic condition and t | Arthritis, Musculoskeletal and Skin Diseases Research | September 23, 2021 | $252,039 |
| Development of a novel crac channel therapeutic for the treatment of primary hyperhidrosis - vivreon biosciences, LLC 4940 carroll canyon rd., ste. 110 san diego, ca 92121 milton@vivreonbiosciences.com niams PA-21-259 project summary hidrosis is the normal physiological sweat response that contribut | Arthritis, Musculoskeletal and Skin Diseases Research | September 8, 2022 | $245,256 |
Questions people ask
How much federal grant money does Vivreon Biosciences LLC get?
$12.9 million in 12 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Vivreon Biosciences LLC the most?
The Department of Health and Human Services, with $12.9 million in 12 awards.
What is Vivreon Biosciences LLC's largest federal grant?
$2.8 million under Drug Use and Addiction Research Programs, with its first action in the period on July 6, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Vivreon Biosciences LLC?
Its largest are Aging Research, Drug Use and Addiction Research Programs and Allergy and Infectious Diseases Research.
Other grant recipients in San Diego
- San Diego Association of Governments
- Metropolitan Transit System
- General Atomics
- Neighborhood House Association
- San Diego County Regional Airport Authority
- San Diego State University Foundation
- San Diego Unified School District
- Family Health Centers of San Diego Inc
Largest federal grant recipients in California · Federal grants in California